ECSP993166A - SERTRALINA ORAL CONCENTRATE - Google Patents

SERTRALINA ORAL CONCENTRATE

Info

Publication number
ECSP993166A
ECSP993166A ECSP993166A ECSP993166A EC SP993166 A ECSP993166 A EC SP993166A EC SP993166 A ECSP993166 A EC SP993166A EC SP993166 A ECSP993166 A EC SP993166A
Authority
EC
Ecuador
Prior art keywords
provides
present
sertralina
pharmaceutically acceptable
concentrated
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Willard Mckowan Welch
Nancy Jane Harper
Gautam R Ranade
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP993166 priority Critical patent/ECSP993166A/en
Publication of ECSP993166A publication Critical patent/ECSP993166A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona una composición farmacéutica concentrada líquida esencialmente no acuosa para la administración oral, que contiene sertralina o una sal farmacéuticamente aceptable de la misma y uno o más excipientes farmacéuticamente aceptables. La presente invención tambien proporciona un uso de esta composición concentrada para preparar una solución acuosa de sertralina. Además, la presente invención proporciona un procedimiento de uso de esta composición concentrada para tratar o prevenir una diversidad de enfermedades o afecciones. Finalmente, la presente invención proporciona el compuesto metanosulfonato de (1S-cis)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-N-metil 1 naftalenoamina.The present invention provides an essentially non-aqueous liquid concentrated pharmaceutical composition for oral administration, containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrated composition to prepare an aqueous sertraline solution. Furthermore, the present invention provides a method of using this concentrated composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound (1S-cis) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-N-methyl 1 naphthalenoamine methanesulfonate.

ECSP993166 1999-10-05 1999-10-05 SERTRALINA ORAL CONCENTRATE ECSP993166A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP993166 ECSP993166A (en) 1999-10-05 1999-10-05 SERTRALINA ORAL CONCENTRATE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP993166 ECSP993166A (en) 1999-10-05 1999-10-05 SERTRALINA ORAL CONCENTRATE

Publications (1)

Publication Number Publication Date
ECSP993166A true ECSP993166A (en) 1999-11-29

Family

ID=42044154

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP993166 ECSP993166A (en) 1999-10-05 1999-10-05 SERTRALINA ORAL CONCENTRATE

Country Status (1)

Country Link
EC (1) ECSP993166A (en)

Similar Documents

Publication Publication Date Title
ES2088312T3 (en) CONTROLLED RELEASE FORMULATION CONTAINING TRAMADOL.
AR035927A1 (en) LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR
DE69906518D1 (en) DRUG DISPENSING SYSTEM CONTAINS A SOLID, SOLID, DRY-BASED BASIS
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR0114799A (en) Cyanophenoxy carboxylic acid compounds and compositions for releasing active agents
UY27533A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING OXIBUTININE
BR0015624A (en) Use of a compound, compound, pharmaceutical composition, and method of treatment or prophylaxis of human diseases or conditions
BRPI0415953A (en) oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation
GT199900015A (en) PROCEDURE TO TREAT HEART FAILURE
BR0113590A (en) 7-oxopyridopyrimidines
BR0211063A (en) Salts of anticonvulsant derivatives
PA8483301A1 (en) SERTRALINA ORAL CONCENTRATE
AR030630A1 (en) PHARMACEUTICAL COMPOSITIONS
AR029588A1 (en) NEW FORM (R) -N- [5-METHYL-8- (4-METHYLIPIPERAZINE-1-IL) -1,2,3,4-TETRAHYDRO-2-NAFTIL] -4-MORFOLINOBENZAMIDA
ECSP066318A (en) COMPOSITION FOR THE RELEASE OF A WEAK BASE FOR AN EXTENDED PERIOD OF TIME
ECSP993166A (en) SERTRALINA ORAL CONCENTRATE
BR0111743A (en) Farnesyl transferase which inhibits 1,2-ringed quinoline enantiomer
CO5700723A2 (en) USE OF A SPECIFIC CYCLIC AMINE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS TO TREAT AND PREVENT CARDIAC INSUFFICIENCY
DK0768083T3 (en) Use of sertraline to treat patients with post myocardial infarction
AR033807A1 (en) USE OF (R) - (-) - 2- [5- (4-FLUOROPHENYL) -3-PIRIDYLMETHYLAMINOME] -CROMANO AND ITS ACCEPTABLE SALTS FOR PHYSIOLOGICAL USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
GEP20043377B (en) Pharmaceutical Complex
DK0863752T3 (en) Use of alkylamine derivatives such as terbinafine in the manufacture of a medicament for the treatment of concomitant diseases of a helicobacter pylori infection.
GT200000087A (en) POLYMORPH FORMS OF A AZABICICLO CITRATE (2.2.2) OCTAN - 3 - AMINA AND ITS PHARMACEUTICAL COMPOSITIONS.
UY28111A1 (en) NEW ORAL IMMEDIATE RELEASE DOSAGE FORM
AR022348A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SYMPTOMS OF LOWER URINARY TRACT